title: Teriparatide induced delayed persistent hypercalcemia.
abstract: Teriparatide, a recombinant PTH, is an anabolic treatment for osteoporosis that increases bone density. Transient hypercalcemia is a reported side effect of teriparatide that is seen few hours following administration of teriparatide and resolves usually within 16 hours of drug administration. Persistent hypercalcemia, although not observed in clinical trials, is rarely reported. The current case describes a rare complication of teriparatide induced delayed persistent hypercalcemia.
authors.affiliation: Internal Medicine Residency, Fairview/Cleveland Clinic Foundation, Cleveland, OH 44111, USA.
authors.forename: Nirosshan
authors.initials: N
authors.lastname: Thiruchelvam
authors.affiliation: Internal Medicine Residency, Fairview/Cleveland Clinic Foundation, Cleveland, OH 44111, USA.
authors.forename: Jaskirat
authors.initials: J
authors.lastname: Randhawa
authors.affiliation: Internal Medicine Residency, Fairview/Cleveland Clinic Foundation, Cleveland, OH 44111, USA.
authors.forename: Happy
authors.initials: H
authors.lastname: Sadiek
authors.affiliation: Department of Hospital Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
authors.forename: Gaurav
authors.initials: G
authors.lastname: Kistangari